We are thrilled to announce Jérôme Vailland’s appointment as 4P-Pharma’s new Chief Financial Officer. Jérôme Vailland built a solid career with significant contributions at Ernst & Young (EY), where he worked for 10+ years. He gained extensive experience in financial audit, company structuring, transactions, and IPOs across European and American markets, mainly in life sciences.&hellip
The 4P-Pharma team sends you warm wishes for a fantastic year of 2024 filled with success, achievement, and unforgettable moments. We are thrilled to celebrate the first decade of our company foundation. Over the past ten years, we have faced challenges, deepened our understanding, and solved complex scientific questions. Each year has brought us joy,&hellip
Our subsidiary, 4Moving Biotech, dedicated to facing the global challenge of knee osteoarthritis, announces that it has reached a significant milestone by completing patient recruitment for its LASARE Phase I clinical trial. The Phase I trial is designed as a multi-center, randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of intra-articular injection&hellip
We are pleased to announce our company’s participation at CHINA Bio 2023, from September 20 – 21, 2023, in Shanghai, China. Our Chairwoman, Revital Rattenbach, and our CEO, Didier Landais, and Francis Berenbaum, CEO/CMO of our subsidiary, 4Moving Biotech, will attend this event. During the event, Pr. Francis Berenbaum will showcase our subsidiary, 4Moving&hellip
All 4P-Pharma’s team wishes you a happy new 2023! Thank you for all your support.
4P-Pharma is thrilled to share the last video of company portrait galleries realized in collaboration with the magazine Entreprendre to highlight our innovative company activities and story. This video focuses on our clinical vision, aiming to rapidly deliver effective, regenerated, first-in-class therapies for untreated serious diseases with high unmet medical needs. 4P-Pharma has developed a&hellip